Sol Gel Technologies Ltd (SLGL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $60.00 (-7.03%), Market cap $0.24B, 52-week low–high $6.90 ~ $97.97.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license
Financial statements, price targets, institutional (13F) holdings and related news for Sol Gel Technologies Ltd are updated in real time on BlackAll Trade.
Sol Gel Technologies Ltd trades at $60.00 (-7.03%). Real-time quotes and charts are available on BlackAll Trade.
Sol Gel Technologies Ltd has a market cap of about $0.24B.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada,